MedTrace Logo

A Study of Empirical Antifungal Therapy With Itraconazole

NCT01706562 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 138

Last updated 2013-02-20

No results posted yet for this study

Summary

The purpose of this study is to investigate the overall success rate of itraconazole intravenous treatment for a period of more than 7 days.

Conditions

Interventions

DRUG

Itraconazole

Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd., Korea Clinical Trial · Janssen Korea, Ltd., Korea

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-09-30
Completion
2011-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01706562 on ClinicalTrials.gov